News and Events for Glycomine
March 4, 2024
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
December 11, 2023
Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
November 2, 2023
Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG
October 12, 2023
Glycomine Appoints Dr. Rose Marino Chief Medical OfficerÂ
August 30, 2023
Data from Glycomine’s Ongoing Natural History Study Provides Insight into Clinical Measures and Biomarkers for PMM2-CDG
January 9, 2023
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
July 11, 2022
Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors
December 17, 2021
Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
June 29, 2021
Glycomine’s Natural History Study Informs Potentially Lifesaving Update To Standard Of Care For PMM2-CDG Patients
June 23, 2021
Glycomine Closes $68 Million Series B To Advance Into Clinical Trials A Novel Treatment For PMM2-CDG, A Rare Glycosylation Disease
August 1, 2019
Glycomine, Inc. Announces $33 Million Series B Financing To Advance Its Therapy For A Congenital Disease Of Glycosylation
November 16, 2016